Walleye Capital LLC Acquires 207,196 Shares of Integra LifeSciences Holdings Co. (NASDAQ:IART)

Walleye Capital LLC lifted its stake in Integra LifeSciences Holdings Co. (NASDAQ:IART) by 758.7% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 234,506 shares of the life sciences company’s stock after purchasing an additional 207,196 shares during the period. Walleye Capital LLC owned 0.30% of Integra LifeSciences worth $4,261,000 at the end of the most recent quarter.

Other institutional investors have also made changes to their positions in the company. FORA Capital LLC bought a new position in Integra LifeSciences during the third quarter worth about $436,000. MetLife Investment Management LLC boosted its stake in Integra LifeSciences by 129.1% during the 3rd quarter. MetLife Investment Management LLC now owns 39,638 shares of the life sciences company’s stock worth $720,000 after acquiring an additional 22,334 shares during the last quarter. Rubric Capital Management LP bought a new position in Integra LifeSciences during the 3rd quarter worth approximately $5,325,000. Glenmede Trust Co. NA grew its holdings in Integra LifeSciences by 125.9% during the third quarter. Glenmede Trust Co. NA now owns 727,781 shares of the life sciences company’s stock valued at $13,224,000 after purchasing an additional 405,624 shares during the period. Finally, BNP Paribas Financial Markets increased its stake in Integra LifeSciences by 824.5% in the third quarter. BNP Paribas Financial Markets now owns 111,775 shares of the life sciences company’s stock valued at $2,031,000 after purchasing an additional 99,685 shares in the last quarter. 84.78% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

IART has been the subject of several research analyst reports. BTIG Research raised shares of Integra LifeSciences from a “sell” rating to a “neutral” rating in a report on Monday, October 7th. Citigroup increased their price target on Integra LifeSciences from $16.00 to $22.00 and gave the stock a “sell” rating in a report on Tuesday, November 5th. Truist Financial cut their price objective on Integra LifeSciences from $26.00 to $21.00 and set a “hold” rating on the stock in a report on Monday, October 14th. Finally, Bank of America lowered their target price on Integra LifeSciences from $26.00 to $18.00 and set an “underperform” rating for the company in a research note on Monday, October 7th. Three equities research analysts have rated the stock with a sell rating, five have assigned a hold rating and one has assigned a buy rating to the stock. Based on data from MarketBeat.com, Integra LifeSciences currently has a consensus rating of “Hold” and an average target price of $24.00.

Integra LifeSciences Stock Up 0.2 %

NASDAQ:IART opened at $24.58 on Monday. The company has a market cap of $1.90 billion, a PE ratio of -273.11, a PEG ratio of 0.84 and a beta of 1.08. The stock has a 50-day simple moving average of $20.77 and a 200 day simple moving average of $23.98. The company has a debt-to-equity ratio of 0.79, a quick ratio of 0.73 and a current ratio of 1.20. Integra LifeSciences Holdings Co. has a 52-week low of $16.81 and a 52-week high of $45.42.

Integra LifeSciences (NASDAQ:IART) last posted its quarterly earnings data on Monday, November 4th. The life sciences company reported $0.41 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.39 by $0.02. Integra LifeSciences had a negative net margin of 0.42% and a positive return on equity of 12.35%. The company had revenue of $380.80 million for the quarter, compared to the consensus estimate of $375.81 million. During the same period last year, the company earned $0.76 earnings per share. The firm’s revenue was down .4% compared to the same quarter last year. On average, sell-side analysts expect that Integra LifeSciences Holdings Co. will post 2.45 EPS for the current fiscal year.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.